Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Fabhalta

(Rimiducid)

Phase 2Small molecule

BBellicum Pharmaceuticals

Rimiducid is used to treat a rare blood disorder called hereditary angioedema, which causes sudden swelling in various parts of the body. It helps prevent these painful and potentially dangerous swelling episodes.[1] Fabhalta is currently being investigated across 12 indications[3], with its most advanced program in Phase 2.[1]

Fabhalta is one of 290 small molecule programs targeting Stem Cell Transplant. It is currently in Phase 2.

12

Indications

25

Total Trials

13

Active Trials

289

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stem Cell TransplantActive, not recruiting

B-Cell MalignanciesRecruiting

Large B-Cell LymphomaNot yet recruiting

Gastric Cancer, MetastaticNot yet recruiting

Breast CancerNot yet recruiting

MalignanciesActive, not recruiting

Patients With Advanced Solid TumorsRecruiting

Advanced or Metastatic Solid TumorsActive, not recruiting

Multiple MyelomaTerminated

Colorectal CancerActive, not recruiting

Stem Cell TransplantPhase 2

Active, not recruiting

B-Cell MalignanciesPhase 1

Recruiting

Large B-Cell LymphomaPhase 2

Not yet recruiting

Gastric Cancer, MetastaticPreclinical

Not yet recruiting

Breast CancerPhase 1

Not yet recruiting

MalignanciesPhase 1

Active, not recruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Advanced or Metastatic Solid TumorsPhase 1

Active, not recruiting

Multiple MyelomaPhase 2

Terminated

Colorectal CancerPhase 1

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Fabhalta

BBellicum Pharmaceuticals

Lexiscan

Voltaren

Zolymbus

Blenoxane

Bristol-Myers Squibb

Methylthioninium Chloride

PProvepharm SAS

MS Contin

HHikma Pharmaceuticals LLC

Duragesic-100

MS Contin

HHikma Pharmaceuticals LLC

Spravato

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Active, not recruiting

Colorectal Cancer

NCT06358430

Q3 2030

PreclinicalNot yet recruiting

Gastric Cancer, Metastatic

NCT07509008

Q4 2032

Phase 1/2Active, not recruiting

Stem Cell Transplant

NCT01744223

Q1 2033

Phase 1Active, not recruiting

Recurrent Disease

NCT02477878

Clinical

Trials by Indication[1]

Stem Cell Transplant4 trials

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Active, not recruiting·BBellicum Pharmaceuticals·Phase 1/2·NCT01744223·36 enrolled

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Active, not recruiting·BBellicum Pharmaceuticals·Phase 1/2·NCT03301168·120 enrolled

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Terminated·BBellicum Pharmaceuticals·Phase 1/2·NCT02065869·187 enrolled

Show 1 more trial

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT03807063

Multiple Myeloma3 trials

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03958656·13 enrolled

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Recruiting·PPoseida Therapeutics, Inc.·Phase 1·NCT04960579·275 enrolled

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Terminated·PPoseida Therapeutics, Inc.·Phase 1/2·NCT03288493·105 enrolled

Patients With Advanced Solid Tumors1 trial

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06066424·54 enrolled

Post Stem Cell Transplant1 trial

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

No longer available·BBellicum Pharmaceuticals··NCT03639844

B-cell Malignancies1 trial

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Recruiting·PPoseida Therapeutics, Inc.·Phase 1·NCT06014762·120 enrolled

15 more indications

Selected Advanced Solid Tumors1 trial

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Terminated· Regeneron logo

Regeneron·Phase 1·NCT02744287·52 enrolled

Hematologic Malignancies1 trial

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Withdrawn·BBellicum Pharmaceuticals·Phase 1·NCT02786485

Malignancies1 trial

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Active, not recruiting·BBellicum Pharmaceuticals·Phase 1·NCT03459170·15 enrolled

HSCT1 trial

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

Terminated·BBellicum Pharmaceuticals·Phase 2/3·NCT03699475·1 enrolled

Uveal Melanoma1 trial

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Terminated·BBellicum Pharmaceuticals·Phase 1/2·NCT02743611·4 enrolled

Recurrent Disease1 trial

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Active, not recruiting·BBellicum Pharmaceuticals·Phase 1·NCT02477878·10 enrolled

Salivary Gland Cancer1 trial

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Terminated·PPoseida Therapeutics, Inc.·Phase 1·NCT04249947·40 enrolled

Relapsed/Refractory1 trial

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT03016377·17 enrolled

Advanced or Metastatic Solid Tumors1 trial

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Active, not recruiting·PPoseida Therapeutics, Inc.·Phase 1·NCT05239143·180 enrolled

Breast Cancer1 trial

Phase 1b Study Of Allogeneic CAR TROP2/IL15 Transduced TGFBR2 KO CB NK-Cells (TRICK-NK) In Combination With Trastuzumab Deruxtecan (T-Dxd) In Treatment-Refractory Breast Cancers

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07553390·60 enrolled

Systemic Lupus Erythematosus1 trial

A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Patients With Severe, Treatment-refractory Systemic Lupus Erythematosus

Withdrawn· Roche logo

Roche·Phase 1·NCT06984341

Colorectal Cancer1 trial

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06358430·10 enrolled

Gastric Cancer, Metastatic1 trial

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

Not yet recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT07509008·10 enrolled

Large B-cell Lymphoma1 trial

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07164469·100 enrolled

Unspecified1 trial

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Terminated·BBellicum Pharmaceuticals·Phase 1/2·NCT03733249·187 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for Rimiducid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rimiducid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rimiducid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bellicum Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBellicum Pharmaceuticals

Related News